Edition: India  
 
> >

Merck to halt study of mild to moderate Alzheimer's drug

Reuters India Tuesday, 14 February 2017
(Reuters) - Merck & Co Inc said it would halt a late-stage trial of its drug in patients with mild to moderate Alzheimer's disease after an external panel pointed to a lack of effectiveness.
0
shares
Share on
Facebook
Share on
Twitter
Post on 
Reddit
Share by
Email
 
Source: Wochit News - < > Embed

News video: Scientists Disappointed After New Alzheimer's Drug Failed

Scientists Disappointed After New Alzheimer's Drug Failed 00:35

Researchers found that the new promising Alzheimer’s drug verubecestat did not work. Dr. Roger Perlmutter, president of Merck Research Laboratories, stated, “While we are disappointed that a benefit was not observed in this study, our work continues [to study the impact of] verubecestat in people...

You Might Like


Other recent news in Health

A&E cuts will hit 23m people, BRITISH MEDICAL ASSOCIATION saysFew players screened for concussions in last soccer WORLD CUP
Senate delays vote on HEALTH CARE billMajor veterans' groups voice concern over Senate HEALTH BILL
Trump administration moves to withdraw clean-water ruleCHARLIE GARD parents lose European court appeal
CNN now fully exposed as fake news central after senior producer calls Trump-Russia narrative “bulls**t” in new undercover videoWHO hopes Yemeni CHOLERA outbreak is half done at 218,000 cases
"He's a toddler at 3 days old": Mom gives birth to 14.4-POUND BABYTrump must break up the GOOGLE media monopoly for the good of America

Twitter

Environmentally friendly: newsR is hosted on servers powered solely by renewable energy
© 2017 newsR / One News Page Ltd. All Rights Reserved.  |  About us  |  Disclaimer  |  Terms & Conditions  |  Privacy Policy  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  Help  |  Contact us  |  DMCA / Content Removal
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter